Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 12:19322968251331069.
doi: 10.1177/19322968251331069. Online ahead of print.

Use of a Miniaturized Near-Infrared Spectroscopy Device for Type 2 Diabetes Mellitus Screening: Pooled Analysis of the Pilot ANODE01 and ANODE02 Studies

Affiliations

Use of a Miniaturized Near-Infrared Spectroscopy Device for Type 2 Diabetes Mellitus Screening: Pooled Analysis of the Pilot ANODE01 and ANODE02 Studies

Pratik Choudhary et al. J Diabetes Sci Technol. .

Abstract

Background: Current diabetes screening methods are complex, inefficient, and inconvenient, requiring resource-intensive blood sampling. With the increasing prevalence of underdiagnosed type 2 diabetes mellitus (T2DM) worldwide, particularly in low-resource settings and underserved populations, affordable and sustainable mass-screening tools are crucial.

Methods: The accuracy and safety of the miniaturized near-infrared (NIR), full-spectrum spectroscopy Glyconics-DS System in detecting T2DM risk status was assessed by pooling data from two independent pilot studies: ANODE01 and ANODE02. Rapid NIR assessments of glycated nail keratin in 60 repeated spectral readings of fingernails from individuals with or without T2DM focused on detecting dichotomized diabetes risk status (glycated hemoglobin [HbA1c] <6.5%) based on chemometric prediction models, clinical specificity/sensitivity, and true/false positive outcomes. An HbA1c point-of-care assay served as an internal control.

Results: Over 12 000 NIR spectral readings were collected in a female-dominant (58.5%), mostly non-smoking (80.0%), diverse cohort of 200 participants (n = 100 with/n = 100 without T2D). The selected chemometrics prediction model on a diagnostic HbA1c cut-off of 6.5% showed a specificity of 92.9% (95% confidence interval [CI] = 88.5-97.4) and a sensitivity of 34.2% (95% CI = 23.4-45.1), with 71.5% concordance. Chemometric predictions were consistent and reproducible with no relevant impact of anthropometric variables, concomitant conditions/medications, smoking status, and number of spectral assessments/nail or hand dominance on NIR assessment. No adverse events or suspected de novo T2D cases were reported.

Conclusions: This pooled analysis of two independent studies demonstrates the clinical feasibility and high specificity of rapid NIR spectral assessment of T2DM risk, with potential for screening, early detection, and sustainable management across health care settings.

Keywords: glycated keratin; hemoglobin; near-infrared spectroscopy; screening; specificity; type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: PC: Medtronic, Novo Nordisk, Lilly, Sanofi, Abbot, Dexcom, Vertex, Roche, and Insulet; research support: Medtronic, Abbott, Dexcom, and Novo Nordisk. PMP: Consultant; Glyconics Ltd, Altimmune, Speaker’s Bureau; Novartis. JES: Consultant; Glyconics Ltd. DL-P: Employee; Glyconics Ltd. FXCC: AstraZeneca, Abbott, Boehringer Ingelheim, Lilly, Novartis, Novo Nordisk, and Menarini.

Figures

Figure 1.
Figure 1.
Optimization process for staged data analysis and preclinical validation of the algorithm in the ANODE01 and 02 studies. Abbreviation: ROI, region of interest. Adapted from Lazaro-Pacheco D et al.
Figure 2.
Figure 2.
ROC analysis for (a) <6.5% and (b) <6.0% HbA1c cut-off values. (a) <6.5% HbA1c threshold. (b) <6.0% HbA1c threshold. Abbreviations: HbA1c, glycated hemoglobin; ROC, receiver operating characteristic.

Similar articles

References

    1. Xhou B, Rayner AW, Gregg EW, et al.. NCD risk factor collaboration (NCD-RisC). Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. Lancet. 2024;404(10467):2077-2093. - PMC - PubMed
    1. World Health Organization. WHO factsheets diabetes. Accessed February 14, 2025. https://www.who.int/news-room/fact-sheets/detail/diabetes
    1. Sun H, Saeedi P, Karuranga S, et al.. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022:183:109119. - PMC - PubMed
    1. International Diabetes Federation (IDF). IDF Diabetes Atlas, 10th Edition. Brussels, Belgium: 2022. https://diabetesatlas.org/resources/idf-diabetes-atlas-2025/
    1. Centers for Disease Control and Prevention (CDC). National diabetes statistics report. Estimates of diabetes and its burden in the United States. Published 2023. Accessed February 14, 2025. https://stacks.cdc.gov/view/cdc/148231

LinkOut - more resources